Schrödinger Stock: Bunsen Adoption Must Earn the Valuation

Executive Summary

Schrödinger closed October 9 at $27.28, up 3.37% on the day. The stock was 66.2% above its July 13 close, yet 16.3% below its October 5 close of $32.60. Those moves describe both the opportunity and the danger: investors are paying for an expansion in the business that has not yet produced a self-funding operating model. A rebound from a sharp decline is not, by itself, confirmation that the valuation is attractive.

The strongest evidence is commercial rather than social. Second-quarter annual contract value, or ACV, grew 27% to $29.6 million, and Bristol Myers Squibb agreed to deploy Bunsen, the company’s agentic AI co-scientist. The counterweight is equally concrete: quarterly software revenue declined 10% to $32.5 million during a shift toward hosted licensing, and operations lost $41.5 million. The $6.0 million net profit benefited from a $45.9 million gain in the fair value of equity investments; it should not be mistaken for recurring operating profitability.

Daily Price, KAMA 14 and SMA 50

Company Overview: Two Businesses, Different Economics

Schrödinger develops physics-based molecular simulation software for pharmaceutical, biotechnology, materials-science and academic customers. Its economic proposition is to improve decisions before researchers commit to expensive synthesis and testing. A useful prediction can help prioritize experiments; it cannot guarantee that a molecule becomes an approved medicine.

The software business sells a research workflow. The drug-discovery business applies the same platform to collaborative and proprietary programs, creating potential milestone, royalty and equity-investment returns. These exposures should be evaluated separately. Software demand can be measured through contracts and deployment. A drug-development payment depends on scientific, contractual and commercial events that are less predictable.

Bunsen adds an agentic interface to the computational platform. According to the August 5 announcement, it can plan and execute multistep molecular-discovery workflows and interpret results. Its significance is not simply that it uses AI: it could broaden the user base beyond experienced computational chemists and increase throughput for existing specialists. The Bristol Myers Squibb agreement is evidence of an important customer relationship. It is not yet evidence that every customer will expand spending at the same rate.

Industry and Market Analysis

The competitive contest is over validated scientific usefulness, workflow integration and customer economics. General-purpose AI tools can lower the cost of generating hypotheses, but pharmaceutical research also requires reliable molecular predictions and reproducible results. Schrödinger’s opportunity is to combine those requirements with easier access to complex computational methods. Its risk is that alternative tools improve faster, customers bundle competing capabilities, or the additional computing required consumes too much of the incremental revenue.

The addressable opportunity does not remove budget constraints. Large pharmaceutical organizations can sustain multiyear research programs, while smaller biotechnology customers may depend on external financing. In a weaker hiring and demand environment, investors should distinguish a useful scientific product from an immediately defensive stock. Research spending, renewal timing and the financing of collaborators can still be cyclical.

The October 2 CMC Markets analysis places Schrödinger alongside Recursion and Tempus, but their business mixes differ. Computational software licensing, a clinical-development pipeline and diagnostic/data services are not interchangeable revenue models. A premium or discount to an “AI healthcare” peer means little without adjusting for recurring revenue, capital requirements and development risk.

Technical Analysis: Trend Strength Meets a Pullback

The 50-day average rose from $14.49 at the beginning of the displayed window to $22.64 at its end. Price remains well above it, which supports the interpretation that the broader advance has not yet been erased. But the October 9 close was below the $29.31 adaptive average, and KAMA had eased from $29.56 on October 5. The near-term evidence is therefore a pullback within a larger advance, not a clean renewed breakout.

The October 8 low of $25.69 and that day’s $26.39 close identify a recent area to monitor, not guaranteed support. A sustained recovery through the adaptive-average region near $29.31 would improve the short-term picture; an eventual retest of the $32.60 October 5 close would be a separate hurdle. Conversely, renewed weakness toward the rising 50-day average would test how much of September’s enthusiasm survives. These are reference levels, not mechanically reliable entry or exit orders.

RSI of 52.42 is consistent with momentum having cooled without reaching a conventional oversold reading. That matters for investors tempted to call the pullback a bargain solely because the stock has fallen from its recent peak. Technical evidence can help assess timing and exposure, but it cannot determine whether future cash flow justifies the price.

Fundamental Analysis: Read Contracts and Cash Together

The hosted-software transition complicates a superficial reading of revenue. More ratable recognition can reduce near-term reported sales even when underlying contract activity expands. Management attributed Q2’s software revenue decline primarily to that transition. Hosted revenue represented 47% of quarterly software revenue and 30% on a trailing-four-quarter basis. That explanation is plausible, but investors should still require the contract momentum to show up in sustained customer economics.

ACV measures billed contract value using the company’s defined treatment of contract length and billing structure. It is useful precisely because it is less affected by revenue-recognition differences. It is not the same as recurring revenue automatically earned over the next twelve months. Contribution ACV also relates to grants rather than ordinary commercial software contracts, so excluding it helps isolate the customer-adoption question.

The August 5 full-year outlook calls for $218 million–$228 million of ACV, 10%–15% growth, and $65 million–$75 million of drug-discovery revenue. The latter range was raised after the Ajax milestone. These are management forecasts, not completed 2026 results. The stated Q3 outlook of $41 million–$45 million excludes contribution ACV; its comparison with $38.3 million in Q3 2025 requires care because the prior figure included $2.2 million of contribution ACV.

Liquidity is meaningful, but the headline profit is not the cash engine

At June 30, cash and equivalents totaled $287.9 million and marketable securities $125.9 million, or $413.7 million combined, excluding $5.1 million of restricted cash. First-half operating cash use was $48.9 million, while proceeds from sales and dispositions of equity investments were $67.0 million. Cash can rise even when operations consume it; the distinction matters when assessing sustainability.

The balance sheet also shows approximately $108.0 million of current and long-term operating-lease liabilities. Those commitments should not be casually described as bank borrowings. Liquidity provides flexibility to invest and absorb uneven collaboration receipts, but a precise runway calculation would require assumptions about spending, collections, investment realizations and future milestones.

The valuation already pays for improvement

Using the October 9 close and roughly 74.8 million shares in the June 30 balance sheet gives an indicative equity value of about $2.04 billion, not an exact October 9 share-count measurement. Against the $259.0 million trailing revenue reported in Stock Analysis’s October 10 statistics snapshot, that is roughly 7.9 times sales. The multiple includes drug-discovery and contribution revenue, not just recurring software. It therefore cannot be read as a pure subscription-software valuation.

There is no useful positive earnings multiple for valuing a structurally loss-making operation. The investment case must instead connect customer adoption to sustainable gross profit, spending discipline and eventual cash generation. At this valuation, evidence that Bunsen expands commercial contracts would be welcome, but evidence that it improves the economics of serving those customers would be more decisive.

Risk Analysis and Decision Framework

Bull case: Bunsen lowers adoption friction, customers expand contracts, hosted revenue becomes more predictable and operating costs grow more slowly than gross profit. Collaboration receipts provide incremental upside rather than being necessary to sustain the business. This would support a better-quality valuation, but it is an outcome to demonstrate.

Base case: contract growth continues while revenue recognition and discovery payments remain uneven. The company has resources to develop the platform but remains loss-making. That supports a selective Hold, with position size reflecting both scientific uncertainty and equity volatility.

Bear case: Bunsen enthusiasm fails to broaden commercial use, research budgets weaken, or infrastructure and development spending keep cash burn elevated. A sales-multiple contraction could then accompany weaker forecasts. The June balance sheet would cushion the company, not necessarily the stock price.

What would change the recommendation? A stronger Buy case requires sustained commercial ACV expansion paired with clearer cash conversion and a valuation offering room for execution risk. A Sell case would strengthen if contract momentum deteriorates while operating cash use and financing needs rise. No numerical price target is assigned because the evidence does not establish normalized margins or the probability-weighted value of development programs.

Bottom line: Schrödinger offers a credible way to study AI’s usefulness inside scientific workflows. It is not a low-risk healthcare defensive, and a valuable product is not automatically an attractively priced stock. Hold the distinction between adoption, accounting profit and cash generation as firmly as the distinction between a promising molecule and an approved drug.